Germline NF2 variant position constrains somatic second hits and determines clinical severity in Neurofibromatosis Type 2-related schwannomatosis

Germline variant position along the NF2 locus determines clinical severity and constrains the somatic second hit acquired in tumours, with the most deleterious germline variants for merlin associated with milder somatic events.

NF2-related schwannomatosis is an autosomal dominant tumour syndrome with complete penetrance but highly variable expressivity whose determinants remain largely unexplained. The authors comprehensively phenotyped 168 patients over a mean 4.5 years, using a dedicated sequencing panel of NF2 and schwannomatosis genes to identify germline (n = 166) and tumour somatic variants (n = 37), and built a composite clinical and radiological severity score. Germline variants included 42% premature termination, 18% splice-site and 16% large deletions; the composite score predicted worsening clinical function, and unsupervised clustering of clinical data recovered phenotypic groups matching that score, whereas mosaicism was associated neither with the score nor with any other severity marker. The score was significantly associated with germline variant location along the locus, with FERM-F1 and helical domain variants the most severe. Within tumours, germline variants most deleterious for merlin were accompanied by milder somatic second hits at the NF2 locus, and vice versa, which the authors interpret as a second-hit modifier partly explaining variable expressivity.

Synthesis written by Geno'X. For the full original abstract, please refer to the source publication.

If replicated, this observation finally provides a stratification axis usable from the moment of diagnosis: germline variant position, available on any report, could calibrate MRI intervals and prognostic counselling in patients currently followed uniformly. Two methodological caveats weigh heavily: the composite score is built and tested in the same cohort without independent validation, and recruitment at a referral centre receiving complex cases probably over-represents severe phenotypes. The second-hit analysis rests on only 37 tumours, in a non-peer-reviewed preprint, which for now rules out any use in genetic counselling.

Analysis by Dr Thibaut Benquey